IQVIA closed 2025 with strong performance across all segments, delivering near double-digit revenue and EPS growth. The company reported fourth-quarter revenue of $4,364 million and GAAP diluted EPS of $2.99. R&D Solutions saw its strongest quarter for net bookings, and both commercial and clinical businesses experienced strong topline growth. The company also provided optimistic full-year 2026 guidance.

IQVIA delivered solid Q3 2025 results with $4.1 billion in revenue, $331 million in net income, and strong free cash flow of $772 million. The company highlighted robust R&D Solutions demand and continued growth in TAS and CSMS segments.

IQVIA delivered revenue above target and net income at the high end of expectations, driven by strong TAS growth and improved R&D demand indicators.

IQVIA delivered robust first-quarter results with revenue reaching $3.83B and adjusted EPS of $2.70. TAS outperformed, while R&DS backlog growth highlighted long-term demand resilience.

IQVIA reported a revenue of $3,958 million for the fourth quarter of 2024, representing a 2.3% increase on a reported basis and 3.0% at constant currency. GAAP Net Income was $437 million, with GAAP Diluted Earnings per Share at $2.42. Adjusted EBITDA was $996 million. The company reaffirms its 2025 outlook.

IQVIA reported Q3 2024 results with revenue of $3,896 million, a GAAP Net Income of $285 million, and an adjusted EPS of $2.84. The company has updated its full-year 2024 guidance due to delays in mega trials.

IQVIA reported second-quarter revenue of $3,814 million, a 2.3% increase year-over-year. GAAP Net Income was $363 million, with adjusted diluted earnings per share of $2.64. The R&D Solutions segment showed strong bookings of $2.7 billion, and the company updated its full-year 2024 guidance.

IQVIA reported a 2.3% increase in revenue to $3,737 million for Q1 2024. GAAP Net Income was $288 million with a GAAP EPS of $1.56. The R&D Solutions contracted backlog reached $30.1 billion, a 7.9% increase year-over-year.

IQVIA reported a 3.5% increase in revenue for Q4 2023, reaching $3,868 million. GAAP Net Income increased significantly to $469 million, and GAAP Diluted Earnings per Share rose to $2.54. The company issued full-year 2024 guidance, projecting revenue between $15,400 million and $15,650 million.

IQVIA reported a 4.9% year-over-year revenue increase in Q3 2023, reaching $3,736 million. Net income grew by 7.1% to $303 million, and adjusted EBITDA increased by 9.1% to $888 million. The R&DS segment demonstrated notable strength, with a book-to-bill ratio of 1.24x and backlog growth of 12%.

IQVIA reported a revenue of $3,728 million, a 5.3% increase year-over-year. GAAP Net Income was $297 million, up 16.0% year-over-year. Adjusted Diluted Earnings per Share was $2.43, a 0.4% decrease year-over-year.

IQVIA's first-quarter 2023 results showed revenue of $3,652 million, a GAAP net income of $289 million, and an adjusted EBITDA of $851 million. The company reaffirmed its full-year 2023 guidance.

IQVIA's Q4 2022 results showed revenue of $3,739 million, a 2.8% increase, and GAAP Net Income of $227 million. The company's Adjusted Diluted Earnings per Share was $2.78, up 9.0% year-over-year, and Adjusted EBITDA was $920 million, an 11.1% increase year-over-year. R&D Solutions quarterly bookings were over $3.1 billion, with a book-to-bill ratio of 1.51x.

IQVIA's third-quarter 2022 results showcased strong financial performance. Revenue reached $3,562 million, a 5.0% increase year-over-year. GAAP Net Income grew by 8.4% to $283 million, with adjusted diluted earnings per share increasing by 14.3% to $2.48. The company's R&D Solutions also saw quarterly bookings exceeding $2.5 billion.

IQVIA's second-quarter 2022 results showed revenue of $3,541 million, a 3.0 percent increase year-over-year, and GAAP net income of $256 million, up 46.3 percent year-over-year. Adjusted diluted earnings per share grew by 14.6 percent to $2.44, and R&D Solutions continued its strong bookings momentum with over $2.6 billion in net new business.

IQVIA reported a strong first quarter with revenue increasing by 4.7 percent year-over-year to $3,568 million. GAAP Net Income grew by 53.3 percent year-over-year to $325 million, and Adjusted EBITDA increased by 9.1 percent year-over-year to $812 million. The company also achieved record R&D Solutions services bookings and backlog.

IQVIA reported a strong Q4 2021 with revenue of $3,636 million, a 10.2% increase year-over-year. GAAP net income grew by 167.2% to $318 million, and adjusted diluted EPS increased by 20.9% to $2.55. The company also raised its full-year 2022 profit guidance.

IQVIA reported strong third-quarter results with a 21.7% increase in revenue to $3,391 million and a 158.4% increase in GAAP net income to $261 million. The company also raised its full-year 2021 guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS.

IQVIA reported strong second-quarter 2021 results, exceeding targets across key financial metrics. Revenue increased by 36.4% year-over-year, and the company raised its full-year 2021 financial guidance due to sustained market momentum.

IQVIA reported strong first-quarter results with revenue of $3,409 million, a 23.8% increase year-over-year, and adjusted diluted earnings per share of $2.18, a 45.3% increase year-over-year. The company raised its full-year 2021 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS.

IQVIA reported a strong fourth quarter in 2020, with revenue reaching $3,298 million, a 13.9% increase year-over-year. Adjusted diluted EPS grew by 21.3% year-over-year to $2.11, and the company raised its full-year 2021 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS.

IQVIA reported third-quarter results with revenue of $2,786 million and Adjusted EBITDA of $604 million. The company raised full-year 2020 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS and provided a full-year 2021 outlook for revenue $12,300 million to $12,600 million, Adjusted EBITDA $2,725 million to $2,800 million and Adjusted Diluted EPS $7.65 to $7.95.

IQVIA reported second-quarter revenue of $2,521 million and adjusted EBITDA of $483 million. The company's R&D Solutions backlog grew 13.5% year-over-year to $20.5 billion. Due to better than expected performance, the company raised its full-year 2020 guidance for revenue, adjusted EBITDA and adjusted diluted earnings per share.

IQVIA's first-quarter revenue reached $2,754 million, with adjusted diluted earnings per share at $1.50. The R&D Solutions quarterly net book-to-bill ratio was 1.42x including pass throughs, and the contracted backlog grew 14% year-over-year to $19.6 billion.

IQVIA's Q4 2019 revenue reached $2,895 million, with adjusted diluted earnings per share of $1.74, a 16.0 percent increase year-over-year. The company highlighted significant wins in Technology & Analytics Solutions and continued strong momentum in R&DS.